Table 1.

Initial characteristics of the 500 adult patients with HL at CS IA and IIA included in the H81 and H90 trials




Group A

Group B

Group C
No. of patients   42   144   314  
No. male/no. female (ratio)   31/11 (2.8)   103/41 (2.5)   122/192 (0.6)  
Age    
Below 40 y, no.   30   90   255  
At least 40 y, no.   12   54   59  
Site of initial node    
Upper cervical, no.   19   70   16  
Axillary/epitrochlear, no.   9   11   5  
Inguinal/pelvic, no.   11   18   0  
Supraclavicular, no.   3   45   228  
Mediastinal, no.   0   0   65  
Clinical stages    
Peripheral IA, no.   21   68   0  
Other IA, no.   3   22   25  
IIA, no.   18   54   289  
Hemoglobin level, g/dL*  14.4 ± 0.2   14.1 ± 0.1   13.1 ± 0.1  
Leukocytes, × 109/L*  7.0 ± 0.3   8.3 ± 0.3   10.4 ± 0.2  
Lymphocytes, × 109/L*  2.1 ± 0.1   1.9 ± 0.7   1.7 ± 0.4  
Platelets, × 109/L*  256.1 ± 1.1   305.9 ± 7.2   355.5 ± 6.4  
Sedimentation rate, mm/h*
 
9 ± 1
 
17 ± 1
 
34 ± 1
 



Group A

Group B

Group C
No. of patients   42   144   314  
No. male/no. female (ratio)   31/11 (2.8)   103/41 (2.5)   122/192 (0.6)  
Age    
Below 40 y, no.   30   90   255  
At least 40 y, no.   12   54   59  
Site of initial node    
Upper cervical, no.   19   70   16  
Axillary/epitrochlear, no.   9   11   5  
Inguinal/pelvic, no.   11   18   0  
Supraclavicular, no.   3   45   228  
Mediastinal, no.   0   0   65  
Clinical stages    
Peripheral IA, no.   21   68   0  
Other IA, no.   3   22   25  
IIA, no.   18   54   289  
Hemoglobin level, g/dL*  14.4 ± 0.2   14.1 ± 0.1   13.1 ± 0.1  
Leukocytes, × 109/L*  7.0 ± 0.3   8.3 ± 0.3   10.4 ± 0.2  
Lymphocytes, × 109/L*  2.1 ± 0.1   1.9 ± 0.7   1.7 ± 0.4  
Platelets, × 109/L*  256.1 ± 1.1   305.9 ± 7.2   355.5 ± 6.4  
Sedimentation rate, mm/h*
 
9 ± 1
 
17 ± 1
 
34 ± 1
 

Group A includes patients with LPHL; group B, patients with cHL without MI; and group C, patients with cHL with MI.

*

Data are mean ± SEM.

or Create an Account

Close Modal
Close Modal